Health
CARB-X funds Phico to develop new intravenous engineered bacteriophage drug – The Pharma Letter
Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop a new intravenous engineered bacteriophage drug to treat
Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop…To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.
Or, if you’re only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing, CRO…
-
General20 hours agoQueensland government expands youth justice laws, David Crisafulli tells UN critics ‘you don’t control me’
-
General22 hours agoRestaurants on the brink as business failures plateau
-
General19 hours agoCharlotte McConaghy calls for climate change action in new novel Wild Dark Shore
-
General12 hours agoThree maps that show the scale of the NSW flood disaster